BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28

• Addex Launches CHF40M Capital Increase With Commitment From Specialist U.S. Healthcare Investors

  Proceeds will extend cash runway through 2022 and fund dipraglurant through the first pivotal registration study in PD-LID.

  February 15, 2018

   · 

  4 min read
• Drug Development

  Zealand Pharma’s Dasiglucagon Phase IIa Results at the 11th International Conference on ATTD

  The aim of the trial was to demonstrate the effectiveness, safety and tolerability of dasiglucagon compared to glucagon for reconstitution in a dual-hormone artificial pancreas system in 12 adults with type 1 diabetes.

  February 15, 2018

   · 

  5 min read
• Business

  Arbutus Enters Exclusivity Agreement With Roivant Sciences

  There are no assurances that Arbutus and Roivant will reach an agreement regarding any such transaction or that any such transaction will be consummated.

  February 15, 2018

   · 

  3 min read
• Policy

  The Guardant360 Assay Receives Expedited Access Pathway Designation for Breakthrough Devices From FDA

  The Guardant360 assay received an Expedited Access Pathway designation from the United States Food and Drug Administration, Guardant Health announced. If approved, the Guardant360 assay could be the first FDA-approved comprehensive liquid biopsy.

  February 15, 2018

   · 

  2 min read
• Business

  Oncoceutics and Calvert Research Announce Development/Investment Agreement for ONC 206

  Oncoceutics and Calvert Research, LLC announced that the two companies have entered into a second product development and investment partnership agreement, this time to further develop and enable the submission of an IND application for ONC206, Oncoceutics’ next generation molecule.

  February 15, 2018

   · 

  3 min read
• Pharm Country

  Rho to Showcase its Expertise in Neurodegenerative Diseases at 6th World CNS Summit

  Rho, a full-service CRO, will highlight its expertise in CNS research at the World CNS Summit, taking place February 20-22 in Boston.

  February 15, 2018

   · 

  1 min read
• Business

  Mainstay Medical Publishes 2017 Full Year Results

  Mainstay Medical announces today the publication of its 2017 Full Year results and Annual Report.

  February 15, 2018

   · 

  1 min read
• 

  FDA

  Stryker’s Trevo Retriever Becomes First and Only Device Indicated for Treatment Up to 24 Hours

  The expanded indication of Stryker’s clot-removal device is in line with the new AHA/ASA guidelines.

  February 15, 2018

   · 

  4 min read
• Biotech Bay

  LUMEDX to Demonstrate Value of Advanced Analytics at Upcoming HIMSS18

  LUMEDX, a top cardiovascular data intelligence company, will show off the latest in advanced analytics and software solutions at the Healthcare Information and Management Systems Society (HIMSS) annual conference next month.

  February 15, 2018

   · 

  2 min read
• Lone Star Bio

  Moleculin Announces Breakthrough Discovery of a New Molecule for Cancer Treatment

  Moleculin Biotech today announced that, pursuant to its continued collaboration with MD Anderson it has developed and licensed what it believes, based on preclinical testing, is a major breakthrough in its effort to develop a new cancer treatment that selectively kills highly resistant tumors.

  February 15, 2018

   · 

  6 min read